Mutation-Derived Neoantigens for Cancer Immunotherapy
Mutation-derived neoantigens distinguish tumor from normal cells. T cells can sense the HLA-presented mutations, recognize tumor cells as non-self and destroy them. Therapeutically, immunotherapy antibodies can increase the virulence of the immune system by increasing T-cell cytotoxicity targeted to...
Main Authors: | John C. Castle, Mohamed Uduman, Simarjot Pabla, Robert B. Stein, Jennifer S. Buell |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01856/full |
Similar Items
-
Cancer neoantigens and immunogenicity: mutation position matters
by: Aude-Hélène Capietto, et al.
Published: (2020-05-01) -
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
by: Zhi Pang, et al.
Published: (2023-12-01) -
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
by: Jiangping Li, et al.
Published: (2023-08-01) -
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
by: Thomas C. Wirth, et al.
Published: (2017-12-01) -
Targeting neoantigens for cancer immunotherapy
by: Xuan Zhao, et al.
Published: (2021-07-01)